Introduction Executive Summary Proliferative vitreoretinopathy: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Proliferative vitreoretinopathy – DelveInsight’s Analytical Perspective Late Stage Products (Phase III) • Comparative Analysis ADX-2191: Aldeyra Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical and Discovery Stage Products • Comparative Analysis PPP-003: Tetra Bio-Pharma • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Proliferative vitreoretinopathy Key Companies Proliferative vitreoretinopathy Key Products Proliferative vitreoretinopathy- Unmet Needs Proliferative vitreoretinopathy- Market Drivers and Barriers Proliferative vitreoretinopathy- Future Perspectives and Conclusion Proliferative vitreoretinopathy Analyst Views Proliferative vitreoretinopathy Key Companies Appendix

Table 1 Total Products for Proliferative vitreoretinopathy Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Aldeyra Therapeutics • Tetra Bio-Pharma • Aviceda Therapeutics